Evaluation of carotid intima-media thickness and carotid arterial stiffness in children with adenotonsillar hypertrophy

2015 ◽  
Vol 12 (1) ◽  
pp. 103-108 ◽  
Author(s):  
Murat Çiftel ◽  
Berrin Demir ◽  
Günay Kozan ◽  
Osman Yılmaz ◽  
Hasan Kahveci ◽  
...  
2012 ◽  
Vol 3 ◽  
pp. 484-490 ◽  
Author(s):  
Anita Rogowicz-Frontczak ◽  
Aleksandra Araszkiewicz ◽  
Stanislaw Pilacinski ◽  
Dorota Zozulinska-Ziolkiewicz ◽  
Andrzej Wykretowicz ◽  
...  

2013 ◽  
Vol 108 (2) ◽  
pp. S95-S96
Author(s):  
Raymond Wang ◽  
Elizabeth Braunlin ◽  
Kelly Covault ◽  
Andrea Metzig ◽  
Kyle Rudser ◽  
...  

2013 ◽  
Vol 14 (9) ◽  
pp. 622-628 ◽  
Author(s):  
Moemen Mohammed ◽  
Concetta Zito ◽  
Maurizio Cusmà-Piccione ◽  
Gianluca Di Bella ◽  
Francesco Antonini-Canterin ◽  
...  

2000 ◽  
Vol 85 (8) ◽  
pp. 2793-2796 ◽  
Author(s):  
Hiroyuki Koshiyama ◽  
Yoshio Nakamura ◽  
Satsuki Tanaka ◽  
Jun Minamikawa

It has been suggested that bisphosphonates may have some antiatherogenic actions in experimental animals or in vitro, but their effects on the atherogenic process in humans has not been reported. In the present study the effect of etidronate treatment on carotid arterial intima-media thickness was prospectively examined in 57 subjects with type 2 diabetes associated with osteopenia. After 1 yr of therapy with cyclical etidronate (200 mg/day for 2 weeks every 3 months), intima-media thickness showed a decrease (mean ± se, −0.038 ± 0.011 mm), which was significantly different from a change in 57 control subjects (0.023 ± 0.015 mm; P < 0.005). Cardiovascular parameters were not changed after etidronate treatment. These findings suggest that etidronate in clinical dosage may have an antiatherogenic action, at least in type 2 diabetes, although its mechanisms remain to be elucidated.


Sign in / Sign up

Export Citation Format

Share Document